Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Accumulated Expenses (2016 - 2025)

Regenxbio (RGNX) has 12 years of Accumulated Expenses data on record, last reported at $38.4 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 0.84% year-over-year to $38.4 million; the TTM value through Dec 2025 reached $38.4 million, up 0.84%, while the annual FY2025 figure was $38.4 million, 0.84% up from the prior year.
  • Accumulated Expenses reached $38.4 million in Q4 2025 per RGNX's latest filing, up from $15.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $76.1 million in Q4 2021 and bottomed at $8.0 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $30.4 million, with a median of $27.7 million recorded in 2023.
  • The widest YoY moves for Accumulated Expenses: up 507.57% in 2022, down 76.26% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $76.1 million in 2021, then crashed by 76.26% to $18.1 million in 2022, then grew by 0.42% to $18.1 million in 2023, then skyrocketed by 109.8% to $38.1 million in 2024, then grew by 0.84% to $38.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $38.4 million in Q4 2025, $15.1 million in Q3 2025, and $35.6 million in Q2 2025.